Abatacept

Generic Name
Abatacept
Brand Names
Orencia
Drug Type
Biotech
Chemical Formula
-
CAS Number
332348-12-6
Unique Ingredient Identifier
7D0YB67S97
Background

Abatacept is a soluble fusion protein, which links the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). Structurally, abatacept is a glycosylated fusion protein with a MALDI-MS molecular weight of 92,300 Da and it is a homodimer of tw...

Indication

Abatacept is indicated in adult patients for the treatment of moderately-to-severely active rheumatoid arthritis and for the treatment of active psoriatic arthritis. In patients two years of age and older, abatacept is also indicated for the treatment of moderately-to-severely active juvenile idiopathic arthritis.
...

Associated Conditions
Acute Graft-Versus-Host Disease (GVHD), Moderate to Severe Rheumatoid Arthritis, Polyarticular Juvenile Idiopathic Arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Psoriatic Arthritis
Associated Therapies
-

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - TNFi vs Abatacept

First Posted Date
2020-08-28
Last Posted Date
2021-11-23
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
63013
Registration Number
NCT04529902
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Tofacitinib vs Abatacept

First Posted Date
2020-08-28
Last Posted Date
2021-11-16
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
29464
Registration Number
NCT04529876
Locations
🇺🇸

Brigham and Women's Hospital, Boston, Massachusetts, United States

Abatacept for Patients With COVID-19 and Respiratory Distress

Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2020-07-20
Last Posted Date
2020-07-20
Lead Sponsor
Beth Israel Deaconess Medical Center
Registration Number
NCT04477642
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

Abatacept for the Treatment of Giant Cell Arteritis

Phase 3
Recruiting
Conditions
Interventions
First Posted Date
2020-07-17
Last Posted Date
2024-08-20
Lead Sponsor
University of Pennsylvania
Target Recruit Count
78
Registration Number
NCT04474847
Locations
🇨🇦

St. Joseph's Healthcare, Hamilton, Ontario, Canada

🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

🇺🇸

Hospital for Special Surgery, New York, New York, United States

and more 4 locations

Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis

Phase 2
Recruiting
Conditions
Interventions
First Posted Date
2020-05-08
Last Posted Date
2024-08-20
Lead Sponsor
Boston Children's Hospital
Target Recruit Count
160
Registration Number
NCT04380740
Locations
🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Boston Children's Hospital, Boston, Massachusetts, United States

🇺🇸

City Of Hope National Medical Center, Duarte, California, United States

and more 11 locations

Study to Assess Safety and Effectiveness of Branebrutinib Treatment in Participants With Active Systemic Lupus Erythematosus or Primary Sjögren's Syndrome, or Branebrutinib Treatment Followed by Open-label Abatacept Treatment in Study Participants With Active Rheumatoid Arthritis

First Posted Date
2019-12-05
Last Posted Date
2024-01-16
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
119
Registration Number
NCT04186871
Locations
🇺🇸

Local Institution - 0083, Spokane, Washington, United States

🇺🇸

Local Institution - 0024, Encino, California, United States

🇫🇷

Local Institution - 0075, Brest, France

and more 71 locations

Early Markers of Disease and Response to Therapy

Early Phase 1
Completed
Conditions
Interventions
First Posted Date
2019-10-08
Last Posted Date
2024-06-04
Lead Sponsor
Sandra Lord, MD
Target Recruit Count
60
Registration Number
NCT04118153
Locations
🇺🇸

Benaroya Research Institute, Seattle, Washington, United States

🇺🇸

Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

First Posted Date
2019-04-29
Last Posted Date
2024-09-30
Lead Sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Target Recruit Count
74
Registration Number
NCT03929601
Locations
🇺🇸

Childrens Hospital of Orange County, Orange, California, United States

🇺🇸

Stanford University, Palo Alto, California, United States

🇺🇸

University of California San Francisco, San Francisco, California, United States

and more 16 locations

Acute GVHD Suppression Using Costimulation Blockade to Expand Non-malignant Transplant

Phase 2
Active, not recruiting
Conditions
Interventions
First Posted Date
2019-04-23
Last Posted Date
2024-04-19
Lead Sponsor
Emory University
Target Recruit Count
30
Registration Number
NCT03924401
Locations
🇺🇸

University of Mississippi Medical Center, Children's Center for Cancer and Blood Disorders, Jackson, Mississippi, United States

🇺🇸

Columbia University Irving Medical Center, New York, New York, United States

🇺🇸

Nemours/Alfred I. DuPont Hospital for Children, Wilmington, Delaware, United States

and more 6 locations

A Study to Evaluate Biomarkers to Predict Efficacy of Abatacept in Rheumatoid Arthritis

Phase 4
Completed
Conditions
Interventions
First Posted Date
2019-03-20
Last Posted Date
2024-07-30
Lead Sponsor
University of Washington
Target Recruit Count
25
Registration Number
NCT03882008
Locations
🇺🇸

University of Washington, Seattle, Washington, United States

© Copyright 2024. All Rights Reserved by MedPath